Genetic Diseases
-
Prader-Willi Syndrome (PWS)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,500.00 – $19,500.00Select optionsThe Prader-Willi Syndrome (PWS) market is hugely contributed by current standard of care (human growth hormone therapy) as there is no cure for PWS. By 2032, the market is expected to change due to the uptake and launch of new novel therapies. In a PWS treatment setting, the current SoC will decline, and the novel emerging drugs will grasp the highest market shares. The sales of the emerging therapies for the treatment of PWS in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2018-2032 study period, adding a value estimated at a total market of $ 2.1 billion by 2032.
-
Wolfram Syndrome (WS) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2030
$6,500.00 – $19,500.00Select optionsNovel therapies designed for this ultra-rare disorder, Wolfram Syndrome (WS) may have broader implications for more common medical conditions related to ER stress and dysfunction. The tools and therapeutic efforts targeting Wolfram syndrome has benefitted in identifying novel treatment modalities for more prevalent disorders such as diabetes mellitus and neurodegenerative disease.